CAJ | 학술논문

目的：探讨奈达铂联合依托泊苷治疗小细胞肺癌的临床疗效。方法将67例小细胞肺癌患者随机分配，采用奈达铂联合依托泊苷治疗的为实验组，顺铂联合依托泊苷作为对照组，比较2组患者的临床疗效、1年生存率和不良发应的情况。结果实验组的临床效果优于对照组。2组1年生存率分别为52．4％和51．6％，P＝0．365。实验组的呕吐和神经毒性、肝肾功能异常的发生率明显低于对照组，P＜0．05，差异具有统计学意义。结论奈达铂联合依托泊苷治疗小细胞肺癌的临床疗效确切，且某些毒副作用较轻，值得临床进一步探讨和研究。
목적：탐토내체박연합의탁박감치료소세포폐암적림상료효。방법장67례소세포폐암환자수궤분배，채용내체박연합의탁박감치료적위실험조，순박연합의탁박감작위대조조，비교2조환자적림상료효、1년생존솔화불량발응적정황。결과실험조적림상효과우우대조조。2조1년생존솔분별위52．4％화51．6％，P＝0．365。실험조적구토화신경독성、간신공능이상적발생솔명현저우대조조，P＜0．05，차이구유통계학의의。결론내체박연합의탁박감치료소세포폐암적림상료효학절，차모사독부작용교경，치득림상진일보탐토화연구。
Objective To explore the clinical efficacy of nedaplatin plus etoposide for small cell lung cancer .Methods 67 cases of small cell lung cancer patients were randomly divided into 2 groups .The research group received nedaplatin plus eto-poside,and the control group received cisplatin plus etoposide .Clinical efficacy,1-year survival rates and side effects of the 2 groups were compared .Results Clinical efficacy of the research group was superior to the control group .1-year survival rates of the 2 groups were 52.4%and 51.6%respectively,P=0.365.Vomiting and neurological toxicities ,liver and kidney dysfunction of the experimental group were obviously lower than those of the control group ,P<0.05,the difference was statistically signifi-cant.Conclusion Nedaplatin plus etoposide for small cell lung cancer is effective with tolerable side effects ,and it is worthy of further exploration and research .